Richard I. Steinhart Joins Atossa Genetics' Board of Directors
SEATTLE, WA -- (Marketwired) -- 03/03/14 -- Atossa Genetics Inc.
(NASDAQ: ATOS), announced today that Richard I. Steinhart has joined
the Company's Board of Directors and has been appointed a Member of
the Audit Committee and Compensation Committee.
"Richard Steinhart brings a wealth of experience addressing the
business needs of development stage, technology driven companies,
including device and pharmaceutical companies," said Dr. Steven Quay,
Chairman, President and CEO. "His expertise will add great value to
Atossa's Board of Directors and the Audit and Compensation
Committees. I'm confident that Richard's contributions will be
invaluable as we continue to advance our product pipeline."
Mr. Steinhart has had a successful career on Wall Street and is a
veteran of the life sciences industry. From 2006 through 2013, he was
an executive at MELA Sciences, most recently serving as its CFO and
Senior Vice President. From1992 to 2006, Mr. Steinhart was a Managing
Director at Forest St. Capital/SAE Ventures. Earlier, he served as
Vice President and CFO at Emisphere Technologies from 1991 to 1992
and as General Partner and CFO of CW Group Inc. Mr. Steinhart is
currently a Member of the Board of Directors of Actinium
Pharmaceuticals, Chairman of its Audit Committee and a member of the
Compensation Committee. From 2004 to 2012, Mr. Steinhart was a Member
of the Board of Directors of Manhattan Pharmaceuticals and was
Chairman of the Audit Committee. Mr. Steinhart is a Certified Public
Accountant (inactive) in New York State and holds a MBA with Honors
from Pace University.
"Atossa Genetics brings unique assets and capabilities that I believe
will play a very important role in improving women's health over the
coming years," commented Mr. Steinhart. "I am excited about joining
Atossa's Board of Directors and look forward to working closely with
management and the Board to realize the full potential of this
About Atossa Genetics
Atossa Genetics Inc. is focused on proprietary products and services
related to breast health through the commercialization of medical
devices and, through its wholly-owned subsidiary, The National
Reference Laboratory for Breast Health, Inc., the offering of
laboratory services and tests. For additional information, please
Forward-looking statements in this press release are subject to risks
and uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the risks
and uncertainties associated with actions by the FDA, including
timing of review by the FDA of 510(k) submissions, and actions
related thereto, the outcome or timing of regulatory clearances
needed by Atossa to sell its products, responses to regulatory
matters, Atossa's ability to continue to manufacture and sell its
products, recalls of products, the efficacy of Atossa's products and
services, performance of distributors, estimated future expenses and
cash needs, and other risks detailed from time to time in Atossa's
filings with the Securities and Exchange Commission, including
without limitation its periodic reports on Form 10-K and 10-Q, each
as amended and supplemented from time to time.
Atossa Genetics Inc.
CFO and General Counsel
MBS Value Partners
Matthew D. Haines (Investors and Media)
Press spacebar to pause and continue. Press esc to stop.